Last reviewed · How we verify
Propofol and Alfentanil
Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through GABA receptor potentiation and opioid receptor activation, respectively.
Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through GABA receptor potentiation and opioid receptor activation, respectively. Used for Induction and maintenance of general anesthesia for surgical procedures, Sedation in intensive care unit settings.
At a glance
| Generic name | Propofol and Alfentanil |
|---|---|
| Sponsor | North District Hospital |
| Drug class | Intravenous anesthetic combination (hypnotic + opioid) |
| Target | GABA-A receptor (propofol); mu opioid receptor (alfentanil) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Propofol is an intravenous hypnotic agent that enhances inhibitory GABA-A receptor signaling in the central nervous system, producing sedation and unconsciousness. Alfentanil is a rapid-acting synthetic opioid agonist that binds mu opioid receptors to provide analgesia and potentiate sedation. This combination is commonly used for balanced anesthesia during surgical procedures.
Approved indications
- Induction and maintenance of general anesthesia for surgical procedures
- Sedation in intensive care unit settings
Common side effects
- Hypotension
- Respiratory depression
- Bradycardia
- Injection site pain (propofol)
- Nausea and vomiting
- Apnea
Key clinical trials
- EEG and Pain Monitor Data Under Anesthesia to Study Pharmacodynamic Effects of Opioids and Sedatives (NA)
- Remimazolam for Bronchoscopy in High-Risk Patients (PHASE4)
- A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined With Alfentanil for Anesthesia in Thoracic Surgery (PHASE4)
- Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement (PHASE4)
- Standardised Drug Provocation Testing in Perioperative Hypersensitivity (NA)
- Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery (NA)
- Patient-Controlled Sedation in Port Implantation (PACSPI-2) (PHASE4)
- Ciprofol Versus Propofol in Patients Undergoing Painless Hysteroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propofol and Alfentanil CI brief — competitive landscape report
- Propofol and Alfentanil updates RSS · CI watch RSS
- North District Hospital portfolio CI